Investing
Anthera, Orexigen Submerge in Monday's 52-Week Low Club
Published:
Last Updated:
March 12, 2018: Here are four stocks trading with heavy volume among 39 equities making new 52-week lows in Monday’s session. On the NYSE advancers led decliners by around 8 to 7 and on the Nasdaq, advancers led decliners by about the same ratio.
Anthera Pharmaceuticals Inc. (NASDAQ: ANTH) traded down about 85% Monday and posted a new 52-week and all-time low of $0.40 after closing Friday at $2.64. The stock’s 52-week high is $5.60. Volume was more than 30 times the daily average of around 1.7 million shares. The company’s Sollpura treatment failed a phase 3 trial.
Orexigen Therapeutics Inc. (NASDAQ: OREX) traded down about 78% Monday and posted a new 52-week low of $0.31 after closing Friday at $1.40. The stock’s 52-week high is $4.46. Volume was around 7.5million, about 15 times the daily average. The company has filed for Chapter 11 bankruptcy.
VEON Ltd. (NASDAQ: VEON) fell about 2.2% Monday to match a 52-week low of $2.61 after closing at $2.67 on Friday. The 52-week high is $4.47. Volume of around 6.7 million was about 30% above the daily average. The company had no specific news.
New Gold Inc. (NYSEAMERICAN: NGD) dropped about 2.9% Monday to post a new 52-week low of $2.35. Shares closed at $2.42 on Friday and the stock’s 52-week high is $4.25. Volume was about 10% below the daily average of around 5.8 million shares. The gold mining company had no news.
Want to Retire Early? Start Here (Sponsor)
Want retirement to come a few years earlier than you’d planned? Or are you ready to retire now, but want an extra set of eyes on your finances?
Now you can speak with up to 3 financial experts in your area for FREE. By simply clicking here you can begin to match with financial professionals who can help you build your plan to retire early. And the best part? The first conversation with them is free.
Click here to match with up to 3 financial pros who would be excited to help you make financial decisions.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.
Latest from 24/7
